| Home > Publications Database > Biallelic LGI1 and ADAM23 variants cause hippocampal epileptic encephalopathy via the LGI1-ADAM22/23 pathway. |
| Journal Article | DZNE-2025-01136 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2025
Oxford Univ. Press
Oxford
This record in other databases:
Please use a persistent id in citations: doi:10.1093/brain/awaf202
Abstract: Monoallelic pathogenic variants in LGI1 cause autosomal dominant epilepsy with auditory features with onset in childhood/adolescence. LGI1 is a secreted neuronal protein, functions as a ligand for ADAM22/23, and regulates excitatory synaptic transmission and neuronal excitability in the brain. While biallelic ADAM22 variants cause developmental and epileptic encephalopathy (DEE), the whole picture of LGI1-ADAM22/23 pathway-related diseases remains incompletely understood. Through international genetic data sharing, we identified the first ultra-rare biallelic LGI1 variants in six individuals from four consanguineous families. Affected individuals presented DEE with neonatal/infantile-onset epilepsy (n = 6/6), global developmental delay/intellectual disability (n = 6/6) and infant/premature death (n = 5/6). Brain MRI showed mild cerebral atrophy in a subset of patients (n = 3/6). Functional analyses revealed that all LGI1 variants result in reduced secretion and ADAM22-binding. Residual LGI1 function levels correlated with clinical severity, ranging from infantile lethality to intermediate phenotypes. Further, we observed epileptic discharges from the isolated whole hippocampus of Lgi1-/- knockout mice, experimentally modelling the hippocampal origin of LGI1-related epilepsy. Automated behavioural analysis of a mouse model for ADAM22-related DEE revealed its impaired cognitive function. Furthermore, we report the first ADAM23 variant associated with lethal neonatal-onset epilepsy and myopathy. Collectively, this study defines the LGI1-ADAM22/23 pathway-related disease spectrum.
Keyword(s): Humans (MeSH) ; Animals (MeSH) ; ADAM Proteins: genetics (MeSH) ; ADAM Proteins: metabolism (MeSH) ; Male (MeSH) ; Female (MeSH) ; Hippocampus: metabolism (MeSH) ; Hippocampus: physiopathology (MeSH) ; Mice (MeSH) ; Intracellular Signaling Peptides and Proteins: genetics (MeSH) ; Infant (MeSH) ; Nerve Tissue Proteins: genetics (MeSH) ; Nerve Tissue Proteins: metabolism (MeSH) ; Child, Preschool (MeSH) ; Child (MeSH) ; Epilepsy: genetics (MeSH) ; Pedigree (MeSH) ; Signal Transduction: genetics (MeSH) ; Adolescent (MeSH) ; Mice, Knockout (MeSH) ; ADAM22 ; ADAM23 ; LGI1 ; MAGUK ; developmental and epileptic encephalopathy ; drug-resistant seizures ; ADAM Proteins ; ADAM22 protein, human ; LGI1 protein, human ; ADAM23 protein, human ; Intracellular Signaling Peptides and Proteins ; Nerve Tissue Proteins
|
The record appears in these collections: |